Adam Anderson, MD
Pulmonary Disease · Saint Louis, MONPI 1154632974
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,525 of the $3,760 with a category attached, or 67.2%. Mallinckrodt Enterprises LLC accounts for 95.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $3,607 and has fallen 96.3% since, to $133 in 2024.
Across 5 payments — averaging $751.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$4K
- La Jolla Pharmaceutical Company$133
- Ironshore Pharmaceuticals Inc.$20
Across 5 payments — averaging $2969.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$8K
- Mallinckrodt Hospital Products Inc.$5K
- Mallinckrodt Enterprises LLC$2K
What the payments were for
- Consulting fees$2,52567%
- Speaking & faculty fees$52514%
- Travel & lodging$55715%
- Food & beverage$1534%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 3 | $3,607 |
| La Jolla Pharmaceutical Company | 1 | $133 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,760 in reported general payments places this provider in the 60th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $289,892 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 103 | $77,055 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $17,855 |
| Spiriva RespimatTiotropium Bromide | 17 | $14,570 |
| Mycophenolate Mofetil | 89 | $12,607 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $7,015 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,642 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $5,420 |
| Azathioprine | 102 | $4,830 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,442 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,549 |
| MethotrexateMethotrexate Sodium | 230 | $1,667 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $1,639 |
| Hydroxychloroquine Sulfate | 96 | $1,609 |
| Prednisone | 286 | $919 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Saint Louis
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Edward CharbekSaint Louis$372K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Murali ChakinalaSaint Louis$172K
- Janet LeeSaint Louis$143K
- Ali SadoughiSaint Louis$87K
- Ramsey HachemSaint Louis$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.